Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-10-06 Sale |
2022-10-07 4:16 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
6,754 | $84.37 | $569,835 | 50,380 (Direct) |
View |
| 2022-09-29 Sale |
2022-09-30 4:20 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
6,754 | $77.35 | $522,422 | 57,134 (Direct) |
View |
| 2022-09-22 Sale |
2022-09-26 4:19 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
6,754 | $77 | $520,058 | 63,888 (Direct) |
View |
| 2022-09-15 Sale |
2022-09-19 4:10 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
12,271 | $88.52 | $1,086,222 | 76,159 (Direct) |
View |
| 2022-09-08 Sale(A) |
2022-09-13 4:15 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
6,754 | $81.48 | $550,316 | 77,396 (Direct) |
View |
| 2022-09-09 Sale |
2022-09-12 4:32 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
1,863 | $88 | $163,944 | 84,150 (Direct) |
View |
| 2022-09-06 Sale |
2022-09-07 4:27 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
1,384 | $78.57 | $108,741 | 86,013 (Direct) |
View |
| 2022-09-02 Sale |
2022-09-06 5:16 pm |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
718 | $79.04 | $56,749 | 55,486 (Direct) |
View |
| 2022-09-02 Sale |
2022-09-06 5:15 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
885 | $79.04 | $69,948 | 72,376 (Direct) |
View |
| 2022-09-02 Sale |
2022-09-06 5:14 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
296 | $79.04 | $23,395 | 165,024 (Direct) |
View |
| 2022-09-02 Sale |
2022-09-06 5:12 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
269 | $79.04 | $21,261 | 83,230 (Direct) |
View |
| 2022-09-01 Sale |
2022-09-06 4:19 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
14,796 | $77.5 | $1,146,634 | 87,397 (Direct) |
View |
| 2022-08-03 Sale |
2022-08-04 4:32 pm |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
5,959 | $73.73 | $439,328 | 28,672 (Direct) |
View |
| 2022-08-02 Sale |
2022-08-03 4:44 pm |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Executive Chairman |
837 | $69.66 | $58,305 | 551,176 (Direct) |
View |
| 2022-08-02 Sale |
2022-08-03 4:44 pm |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
437 | $69.66 | $30,441 | 34,631 (Direct) |
View |
| 2022-08-02 Sale |
2022-08-03 4:44 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
414 | $69.66 | $28,839 | 102,193 (Direct) |
View |
| 2022-06-10 Sale |
2022-06-16 4:22 pm |
NovoCure Ltd | NVCR | HILLEMAN JERYL L Director |
407 | $69.61 | $28,331 | 2,537 (Direct) |
View |
| 2022-05-10 Sale |
2022-05-12 4:30 pm |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
4,205 | $63.17 | $265,646 | 34,846 (Direct) |
View |
| 2022-03-09 Sale |
2022-03-11 4:54 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,669 | $71.19 | $261,196 | 86,904 (Direct) |
View |
| 2022-03-07 Sale |
2022-03-09 4:56 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
7,775 | $69.73 | $542,116 | 81,908 (Direct) |
View |
| 2022-03-08 Sale |
2022-03-09 4:55 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
744 | $70.1 | $52,154 | 102,295 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2022-09-15 Exercise |
2022-09-19 4:10 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
5,517 | $7.15 | 76,159 (Direct) |
View |
| 2022-09-15 Exercise |
2022-09-19 4:10 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
5,517 | $0 | 76,159 (Direct) |
View |
| 2022-08-02 Option Award |
2022-08-03 4:45 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
7,122 | $70.2 | 73,261 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:51 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
281 | $59.08 | 49,483 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:50 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
144 | $59.08 | 17,002 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:49 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
251 | $59.08 | 66,139 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:48 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
218 | $59.08 | 165,320 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:48 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
276 | $59.08 | 13,583 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:47 pm |
N/A N/A |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
222 | $59.08 | 35,068 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:46 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
312 | $59.08 | 102,607 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:45 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
312 | $59.08 | 83,499 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:44 pm |
N/A N/A |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
213 | $59.08 | 56,204 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-10 4:12 pm |
N/A 2032-06-08 |
NovoCure Ltd | NVCR | Madden Martin J. Director |
8,700 | $0 | 8,700 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-10 4:11 pm |
N/A 2032-06-08 |
NovoCure Ltd | NVCR | Hung David Director |
6,777 | $0 | 13,491 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-10 4:10 pm |
N/A 2032-06-08 |
NovoCure Ltd | NVCR | Scannell Timothy J Director |
8,700 | $0 | 8,700 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-10 4:10 pm |
N/A 2032-06-08 |
NovoCure Ltd | NVCR | VERNON W ANTHONY Director |
8,700 | $0 | 8,700 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-10 4:09 pm |
N/A 2032-06-08 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
6,777 | $0 | 79,636 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-10 4:08 pm |
N/A 2032-06-08 |
NovoCure Ltd | NVCR | HILLEMAN JERYL L Director |
8,700 | $0 | 8,700 (Direct) |
View |
| 2022-05-05 Gift |
2022-05-09 4:14 pm |
N/A 2026-01-12 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
2,648 | $0 | 147,048 (Indirect) |
View |
Ownership |
2022-04-14 4:36 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
0 | $0 | 50,806 (Direct) |
View |
| 2022-03-03 Exercise |
2022-03-11 4:55 pm |
N/A 2025-04-22 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
3,840 | $15.6 | 73,624 (Direct) |
View |
| 2022-03-03 Exercise |
2022-03-11 4:55 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
1,200 | $11.46 | 73,624 (Direct) |
View |
| 2021-07-31 Exercise |
2022-03-11 4:54 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,717 | $154.01 | 86,904 (Direct) |
View |
| 2021-07-31 Exercise |
2022-03-11 4:54 pm |
2021-07-31 N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,717 | $0 | 86,904 (Direct) |
View |